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Nanotechnology incorporated with molecular biology became a promising way to 
treat cancer. The size of nanoparticles enables them to overcome the side effects noticed in 
cancer treatment like chemotherapy and surgery. Various types and shapes of nanoparticles 
have been synthesized and used in drug delivery to tumor sites. However, one of problems 
of using these nanoparticles is the aggregation after injecting them into human body due to 
flow rate of bloodstream. The coagulation and aggregation will result in clogging blood 
vessel and lower therapeutic efficacy.       
 In this thesis, a solution to the aggregation problem was proposed, which is coating 
biopolymer on nanoparticles (NPs). The experimental sections covered synthesis and 
characterization of breast cancer specific targeting drug-encapsulated NPs and biopolymer 
coating on the surface of Au-Fe3O4 NPs for thermal therapy. Furthermore, in vitro studies 
of these NPs with breast cancer cells were also included. The specific targeting anticancer 
drug-encapsulated NRs showed significant inhibition in BT-474 breast cancer cell growth. 
The Au-Fe3O4 NPs has a possibility to treat cancer cells using the thermal therapy 








 First of all, I would like to express my deepest gratitude to my advisor, Dr. Sutapa 
Barua, for her guidance, time and patience to provide me a great time doing the research. 
This research work would not have completed without her intellectual insight and 
constructive criticism. It has been an honor to be her student.   
 Also, I would like to thank Dr. Daniel Forciniti and Dr. Yue-Wern Huang for their 
guidance and valuable discussion through the research. I would like to thank all of the lab 
members who encouraged me through hard time during the research.  
 I am grateful to my sponsor, the Royal Thai government, for funding and the 
wonderful opportunity to pursue this degree.        
 Last, I would like to thank my family for their encouragement, support and 
unconditional love throughout my life.   









TABLE OF CONTENTS 
Page 
PUBLICATION THESIS OPTION ................................................................................... iii 
ABSTRACT ....................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
LIST OF ILLUSTRATORS ............................................................................................... x 
LIST OF TABLES ............................................................................................................ xii 
SECTION 
1. INTRODUCTION .......................................................................................................... 1 
    1.1. BIODEGRADABLE POLYMER-COATED PARTICLES FOR CANCER     
           TREATMENTS ................................................................................................................. 2 
 
    1.1.1. Polycaprolactone (PCL). ............................................................................... 2 
    1.1.2. Poly (Lactic-Co-Glycolic Acid) (PLGA). ..................................................... 3 
    1.1.3. Polylactic Acid (PLA). .................................................................................. 4 
    1.1.4. Dextran. ......................................................................................................... 6 
    1.1.5. Gelatin. .......................................................................................................... 7 
    1.2. RESEARCH PROBLEM ................................................................................................. 8 
PAPER 
I. BIORESPONSIVE POLYMER COATING ON TARGETED DRUG NANORODS... 9 
ABSTRACT ...................................................................................................................... 10 
vii 
 
KEYWORDS .................................................................................................................... 11 
1. INTRODUCTION ........................................................................................................ 12 
2. MATERIALS AND METHODS .................................................................................. 15 
    2.1 SYNTHESIS OF PCL POLYMER COATED CPT NRs ....................................... 15 
    2.2 CHARACTERIZATION OF CPT-PCL NRs ......................................................... 15 
    2.3 DEGRADATION OF PCL COATING AND STABILITY OF LACTONE   
          FORM OF CPT IN CPT-PCL NRS ........................................................................ 16 
 
    2.4 QUANTIFICATION OF CPT DRUG RELEASE ................................................. 16 
    2.5 CONJUGATION OF ANTIBODY ON THE SURFACE OF CPT-PCL NRs ...... 17 
    2.6 IN VITRO CELL GROWTH INHIBITION ............................................................ 17 
    2.7 STATISTICAL ANALYSIS .................................................................................. 18 
3. RESULTS ..................................................................................................................... 19 
    3.1 PREPARATION OF A THIN LAYER OF PCL COATING ON CPT NRs ........... 19 
    3.2 DEGRADATION OF PCL COATING USING FT-IR SPECTROSCOPY ............ 20 
    3.3 CPT DRUG RELEASE WITH PCL COATING DEGRADATION ........................ 23 
    3.4 PREPARATION OF ANTIBODY TARGETED CPT-PCL-TTZ NRs ................... 24 
    3.5 INHIBITION OF BREAST CANCER CELL GROWTH BY CPT-PCL-TTZ  
          NRs ..................................................................................................................................... 26 
 
4. DISCUSSION ............................................................................................................... 30 
5. CONCLUSIONS........................................................................................................... 33 
6. ACKNOWLEDGMENTS ............................................................................................ 34 
viii 
 
REFERENCES ................................................................................................................. 35 
II. POLYMER COATING ON Au-Fe3O4 NANOPARTICLES ...................................... 41 
ABSTRACT ...................................................................................................................... 41 
1. INTRODUCTION ........................................................................................................ 42 
2. MATERIALS AND METHODS .................................................................................. 44 
    2.1 PLL COATING ON Au-Fe3O4 NANOPARTICLES .................................................. 44 
    2.2 PLL- Au-Fe3O4 NANOPARTICLE CHARACTERIZATION .................................. 44 
    2.3 BT-474 CELL CYTOTOXICITY WITH Au-Fe3O4 NANOPARTICLES .............. 44 
    2.4 IN VITRO CELL APOPTOSIS STUDY ....................................................................... 45 
3.RESULTS ................................................................................................................................. 46 
    3.1 CHARACTERIZATION OF PLL-Au-Fe3O4 NANOPARTICLES ....................... 46 
    3.2 CELLULAR UPTAKE OF Au-Fe3O4 NANOPARTICLES .................................. 46 
    3.3 BT-474 CELL CYTOTOXICITY WITH Au-Fe3O4 NANOPARTICLES ............ 47 
    3.4 EFFECTS OF THE Au-Fe3O4 NANOPARTICLE WITH NIR LASER  
          TO  BT-474 CELLS................................................................................................ 47 
 
4. DISCUSSION ......................................................................................................................... 50 
5. CONCLUSION ....................................................................................................................... 51 
SECTION 
2. CONCLUSIONS AND FUTURE WORKS ................................................................. 52 
BIBLIOGRAPHY ............................................................................................................. 53 
ix 
 









Figure 3.1: TEM images of CPT-PCL NRs. (a) Image showing homogeneous  
distribution of CPT-PCL NRs. (b) Magnified view of a thin (~10 nm;   
arrows) PCL polymer film on CPT NRs. (c) Polymer coating thickness ......19 
 
Figure 3.2: Surface zeta potential of CPT NRs (a) before PCL coating, and (b) after   
 PCL coating as analyzed using DLS. Three colored lines indicate three 
replicates with a symmetric distribution of zeta potential. ............................ 21 
 
Figure 3.3: FT-IR graphs of CPT-PCL NRs at t=0 (dotted line), t=72 h (solid line) and 
CPT NRs without any coating………………………………………………22 
 
Figure 3.4: Cumulative percentage of CPT drug release from CPT-PCL NRs in PBS 
buffer at pH 6 (solid line, solid points) and pH 7.4 (dotted line, open  
points), and at 37C versus time .................................................................... 23 
 
Figure 3.5: The CPT standard curve was used to measure the drug concentrations ........ 24 
 
Figure 3.6: The BSA standard curve was used to measure protein concentrations. ......... 25 
 
Figure 3.7: Growth inhibition curves of HER-2 positive BT-474 cells as determined by 
calcein-AM live dead assay after 72 h incubation. Results are expressed as  
a percentage of PBS-treated control cells versus doses of CPT in CPT-PCL-
TTZ NRs. The data represent average and standard deviation of ten  
treatments in three independent experiments………………………………...28 
 
Figure 3.8: Growth inhibitory effects of CPT-PCL-TTZ NRs on HER-2 negative  
MDA-MB-231 cells. No difference between CPT-PCL-TTZ and CPT-PCL-
BSA control indicates non-targeted CPT mediated cytotoxicity only in  
MDA-MB-231 cell.......................................................................................... 29 
 
PAPER II 
Figure 3.1: TEM image of  (a) uncoated Au-Fe3O4 nanoparticles. (b) PLL coating on  
Au-Fe3O4 nanoparticles. ................................................................................ 46 
 
Figure 3.2: Microscopic images of (a) Cellular uptake of 100 µg/ml of Au-Fe3O4 
nanoparticles inside BT-474 cells. (b) PBS treated BT-474 cells ................. 47 




Figure 3.4: % BT-474 cell death after adding Au-Fe3O4 nanoparticles and exposing to 

























Table 3.1: Characterization of CPT-PCL-TTZ and CPT-PCL-BSA NR conjugates ....... 26 






Invasive diseases like cancer have been a major issue for public health. The current 
cancerous treatment methods such as chemotherapy or surgery still have side effects that 
can cause some troubles to patients.1 Nano-biotechnology, which is the combination of 
nanotechnology and biology, has become a promising way to treat cancer. Many types of 
the particles within the nano-scale were synthesized through various methods. Among all 
the synthetic methods that have been used, there is still a challenge for these nanoparticles. 
For nanoparticles less than 100 nm in size, the long-range force between nanoparticles is 
controlled by Brownian motion, which causes the collision of particles and leads them to 
aggregation.2 A solution to this problem is surface modification including coating 
something on the surface of particles. Coating biocompatible polymer on the particles is 
an interesting technique to help increase the potential of the nanoparticles, including 
anticancer drugs. It does not only increase the potential of the synthesized nanoparticles, 
but also helps reduce the side effects from the drug. Anticancer drugs themselves are 
considered highly toxic to cells. Therefore, specific targeting nanoparticles play an 
important role in treatment to avoid the side effects to other cells. Coating polymer on the 
drug may decrease toxicity and provide a surface for biomolecules like antibodies to 
conjugate on, which would lead to the specific targeting treatment.   
 Apart from polymer-coated anticancer drug nanoparticles, the gold nanoparticles 
were also used to study the hyperthermia induced treatment using the principal of thermal 
therapy. One of the promising multifunctional magnetic nanomaterials is the gold 
magnetite (Au-Fe3O4) nanoparticles. The magnetite nanoparticles have shown the ability 
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for biomedical applications in magnetic resonance imaging and hyperthermia induced 
treatment which eventually leads to cell apoptosis. Although the gold nanoparticles were 
found useful to treat cancer, there is still a drawback in this strategy: low retention time in 
the bloodstream, which caused the particle aggregation and clog blood vessel. To overcome 
this disadvantage, coating polymer on the surface of gold nanoparticles may increase the 
retention time by preventing aggregation. Therefore, this research outlines the synthesis, 
characterization of anticancer drug encapsulated nanoparticles, the conjugation with 
biomolecules on nanoparticles, the coating of biocompatible polymer on gold 
nanoparticles, and in vitro study with breast cancer cells.    
 1.1. BIODEGRADABLE POLYMER-COATED PARTICLES FOR CANCER  
          TREATMENTS 
 
 1.1.1. Polycaprolactone (PCL). PCL is a synthetic biodegradable polymer.3 It is a 
semi-crystalline, hydrophobic polymer in which the crystallinity decreases when molecular 
weight increases. Due to its properties, PCL has attracted much attention for biomedical 
applications.4           
 Ortiz et al. studied the combination of gene therapy and drug encapsulation was 
expected to increase the potential of the therapy. In addition, the biodegradable polymer 
like PCL has an ability to protect antitumor drugs from rapid elimination during in vivo 
studies. The combination of cytosine deaminase/5-fluorocytosine (CD/5-FC) and herpes 
simplex virus thymidine kinase (HSV-tk) was used in colon cancer therapy. The 5-FU drug 
encapsulated nanoparticles were prepared using the solvent emulsion method. From the 
results, the nanoparticles have a spherical shape with diameter of 140 ± 20 nm. Zeta 
potential values also indicated that the drug was entrapped within the nanoparticles. The 
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drug encapsulated nanoparticles were then tested in vitro drug release which showed a drug 
release profile of up to 27% within three hours of the study in neutral pH. The rapid drug 
release resulted from the leakage of the polymer surface in nanoparticles. From in vivo 
study, the 5-FU drug inhibited the cell proliferation in a dose-dependent manner. The 
combination of the 5-FU drug and E gene was investigated to study the cytotoxicity in 
SW480 colon cancer cells. The result showed that this combination increases the 
percentage of apoptotic in cells within 24 hours (83% ± 4.6%), which is greater than the 
independent 5-FU loaded nanoparticles (22% ± 2.5%) and E gene (41% ± 5%). Therefore, 
this study reveals a new strategy for colon cancer using the combination of drug-
encapsulated nanoparticles and gene therapy which is a promising in vitro study. However, 
it needs to have more evidence in vivo.5  
1.1.2. Poly (Lactic-Co-Glycolic Acid) (PLGA). PLGA is a copolymer, which is 
the combination of polylactic acid (PLA) and polyglycolic acid (PGA). It is soluble with a 
wide range of solvents such as tetrahydrofuran, ethylacetate, acetone.6  
 Farazuddin et al. used PLGA microsphere to entrap Perillyl alcohol (POH), which 
was reported as anti-cytotoxic properties against many types of cancer. The POH- 
encapsulated PLGA microparticles were synthesized using the oil-in-water based emulsion 
solvent method. The microparticles were characterized using SEM, which revealed the 
microparticle size of 768 ± 215 nm. The microparticles were further studied during in vitro 
released kinetics. After 168 hours, the overall drug release was about 30%. From an in vitro 
cytotoxicity experiment, the results indicated that the IC50 value of POH loaded 
microparticles was higher than the drug alone. In order to confirm the efficiency of the 
microparticles, they were tested in vivo using skin cancer cells. The free form of the drug 
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was used to compare to the drug - encapsulated microparticles. Within 13 weeks, the 
survival rate of the sample treated with microparticles was ~80%; meanwhile, the sample 
treated with the POH drug alone showed only 40% survival rate. This whole study 
indicated that the drug encapsulated microparticles were successfully synthesized and 
provided higher efficiency than the free formed drug.7    
 Verderio et al. used PLGA nanoparticles to encapsulate the antitumor drug 
curcumin (CUR). CUR has an ability to inhibit carcinogenesis at three stages: tumor 
promotion, angiogenesis, and tumor growth. CUR interacts with TrxR, which is 
overexpressed in tumor cells. TrxR is converted by NADPH oxidase and H2O2 is increased, 
which finally causes the cancer cell death. However, CUR is a hydrophobic drug. In order 
to overcome the problem of extremely rapid metabolism and poor absorption of CUR, this 
drug needs the carrier to bring it to the tumor site. CUR was encapsulated within PLGA 
nanoparticles using the solvent evaporation method. Drug - encapsulated nanoparticles 
were obtained after the centrifugation. The drug-loaded nanoparticles were characterized 
by TEM and SEM. The drug-encapsulated nanoparticles have a spherical shape with a 
diameter of 128.37 ± 6.7 nm. The amount of CUR was calculated using UV-vis and 
fluorescence spectroscopy, which showed about 80% encapsulation in the nanoparticles. 
The drug-loaded PLGA nanoparticles were further used in vitro with MCF7, the HER2+ 
breast cancer cells. The CUR alone was used as a control. The results indicated that after 
incubating MCF7 with nanoparticles for 24 hours, 50 µg/ml of nanoparticles efficiently 
inhibited the tumor growth.8  
 1.1.3. Polylactic Acid (PLA). PLA is a thermoplastic polymer that has high 
strength and high modulus. PLA is in the group of aliphatic polyester polymers.9 It is also 
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degradable through the hydrolysis of ester bond where the hydrolysis rate depends on the 
size and shape of particles.10                                                                                                              
 Zhu et al. used PLA to encapsulate the docetaxel (DTC) for liver cancer treatment. 
The aim of this study is to enhance the drug delivery to targeted tumor sites. The drug- 
encapsulated nanoparticles were prepared using the solvent evaporation method. 
Tocopherol polyethylene glycol 1000 succinate (TPGS), a water-soluble derivative of 
vitamin E, was used as an emulsifier in order to increase the drug encapsulation due to its 
bulky structure and large surface area. After removing the solvent, the surface of the drug 
encapsulated nanoparticles were further coated with polydopamine and then conjugated 
with galactosamine to specifically target liver cancer cells. After the characterization, the 
diameter of sphere-shaped NPs is ~ 209 nm. The nanoparticles were tested for DTC release 
and the result showed that at the initial stage the drug released up to 30% within 2 days of 
the observation. After 14 days, the cumulative DTC released was ~60%. The IC50 value of 
NPs was obtained from the cell viability, which showed that NPs were ~7 fold higher than 
non-targeting NPs. From in vivo results, the Gal-pD-TPGS-PLA NPs could reach the 
targeted tumor site and also inhibit the tumor growth in the liver more efficiently than non-
targeting nanoparticles. The overall results gave a promising strategy for liver cancer 
therapy.11            
 In the study of PLA for breast cancer drug delivery, Jiang et al. used PLA 
incorporated with TPGS to form the nanoparticles. The anticancer drug used in the study 
was doxorubicin (DOX). The photosensitizer was used to induce endolysosome escape of 
the delivery system to reverse the drug resistance and overcome the co-delivery problem. 
This study proposed the combination of chemo-photodynamic therapy for DOX-resistant 
6 
 
human breast adenocarcinoma cells (MCF-7/ADR cells). The nanoparticles were prepared 
using the nanoprecipitation method which, resulted in sphere-shaped nanoparticles with a 
diameter of 140.3 ± 13.45 nm. The surface of the nanoparticles was modified by 
conjugating with tLyp-1 peptide .The nanoparticles were then tested in vitro drug release, 
which showed that 70% of DOX was released at pH 5.5 within 96 hours of the study. After 
using the laser as a trigger of the treatment, the percentage of apoptosis of nanoparticles 
gave the highest percentage of other samples. The result from the in vivo study also 
confirmed that the tLyp-1-NPs with the laser can inhibit the tumor growth in the mice 
model more efficiently than using no laser and the non-treated mice.12 
 1.1.4. Dextran. Dextran is one of the polysaccharide groups which consists of 
repeated monosaccharide units linked by glycosidic bonds. Dextran has been used for 
particles preparation because of its nonionic charges.13    
 Zhang et al. proposed the use of dextran conjugated with doxorubicin in order to 
improve low drug efficiency and side effects to overcome the multidrug resistance. Dox 
was conjugated on the dextran via hydrazone bonds. The selective targeting was also used 
in the study by grafting folate acid on dextran. The size of nanoparticles was ~148 nm in 
diameter. The nanoparticles were tested for drug release in vitro at pH 5.0, which showed 
DOX release up to 92% within 48 hours. The nanoparticles were further tested for cell 
cytotoxicity in HepG2/DOX cells. The results indicated that the folate ligand on the 
prodrugs had a selective targeting ability towards cells that express the folate receptor. 
These nanoparticles were then tested in vivo and the results showed that the targeted drug- 
capsulated nanoparticles could expand the life of treated mice and they also had fewer side 
effects to the heart.14  
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 1.1.5. Gelatin. Gelatin is a polymer that is not only biodegradable, and 
biocompatible, but it also bio-adhesive properties. These important properties indicate that 
gelatin is a material that can easily form film and particles for biomedical applications.15
 Lu et al. studied paclitaxel-loaded gelatin nanoparticles for intravesicle 
chemotherapy, which provides selectively drug delivery at high concentrations to tumor-
bearing bladders while minimizing exposure time in the system. Paclitaxel was chosen 
because of its lipophilicity, which provides the ability to penetrate the urothelium more 
effectively than other drugs. However, entrapping paclitaxel in micelles resulted in 
lowering the drug concentration into the bladder tissue. The solutions to overcome this 
problem are using a surface active agent which is capable of disrupting the micelle structure 
and increasing the free fraction of paclitaxel. The drug-encapsulated gelatin nanoparticles 
were synthesized using the desolvation method. The size of nanoparticles was in the range 
of 600-1,000 nm. These nanoparticles were able to release the paclitaxel ~92% within two 
hours. The nanoparticles can be degraded consistently by protease. The drug-encapsulated 
nanoparticles can inhibit 60% of RT4 cells in 48 hours and its IC50 was lower than free 
formed drug, which showed higher efficiency in inhibiting the growth of cancer cells and 
was confirmed by the same trend in vivo.16      
 Li et al. studied the use of gelatin for encapsulating both hydrophobic CUR and 
hydrophilic DOX for dual targeting HER2-overexpressing breast cancer. The nanoparticles 
were synthesized using a surfactant-free method utilizing amifostine to stably link a 
targeting ligand (Herceptin) to amphiphilic gelatin (AG)-iron oxide-calcium phosphate 
(CaP) nanoparticles with hydrophobic CUR and hydrophilic DOX encapsulated in the AG 
core and CaP shell (AGIO-CaP-CD), respectively. Gelatin entrapped the hydrophobic 
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molecules by using an emulsion method. The nanoparticles were ~200 nm in diameter. 
After 24 hours, DOX showed fast release (~ 60% with pH 5.0) but slow release (~ 10% 
with pH 7.4), which means the nanoparticles were able to inhibit the premature DOX 
release before reaching the targeted tumor site. The drug-encapsulated nanoparticles were 
further tested with SK-BR-3 cells, which showed that the drug-encapsulated nanoparticles 
were more effective than the drug alone and gelatin can be used as a degradation 
controllable material.17  
1.2. RESEARCH PROBLEM 
 In the context of the previous section topic, it can be said that the biodegradable 
polymers are useful for drug delivery in terms of drug degradation protection, drug 
encapsulation, and particle forming. The research problem for this thesis is to propose the 
method to coat the anticancer drug nanoparticles and Au-Fe3O4 nanoparticles in order to 
prevent them from coagulation and aggregation. Additionally, to help increase the potential 
of therapeutic efficacy for delivering nanoparticles for cancer therapy. The upcoming 
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Ineffective drug release at the target site is among the top challenges for cancer 
treatment. The first challenge reflects the fact that interactions with carriers (i.e., 
nanoparticles) can denature the active ingredients of drugs by shear stress. The second 
challenge is low drug release in the disease microenvironment. Here, we report a one-step 
process to prepare bioresponsive polymer coated drug nanorods (NRs) from liquid 
precursors using the solvent diffusion method. A thin layer (10.3  1.4 nm) of poly(-
caprolactone) (PCL) polymer coating was deposited on the surface of camptothecin (CPT) 
anti-cancer drug NRs. The mean size of PCL-coated CPT NRs was 500.9  91.3 nm length 
x 122.7  10.1 nm width. The PCL polymer coating was biodegradable at acidic pH 6 as 
determined by Fourier Transform Infrared (FT-IR) spectroscopy. CPT drugs were released 
up to 51.5% when PCL coating dissolved into non-toxic carboxyl and hydroxyl groups. 
Trastuzumab (TTZ), a humanized IgG monoclonal antibody, was conjugated to the NR 
surface for breast cancer cell targeting. Combination treatments using CPT and TTZ 
decreased the HER-2 positive BT-474 breast cancer cells by 66.9  5.3 % in vitro. These 
results suggest effective combination treatments of breast cancer cells using bioresponsive 
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Protection of molecular structures of drugs is required in order to retain its active 
groups and therapeutic efficiency. For example, the lactone ring of CPT drugs is converted 
to carboxylate form, which possesses high affinity to human serum albumin (HSA) at 
physiological pH 7.4, and is preferentially eliminated from the body.1,2 Encapsulation of 
CPT inside polymer nanoparticles prevents the conversion of CPT into the inactive 
carboxylate form during blood circulation, thus increasing its likelihood of reaching the 
target site.3-6 CPT has been conjugated with a variety of polymers such as β-cyclodextrin,7,8 
N-hydropropylmethacrylamide (HPMA),9 polylactide (PLA),10 polyethylene glycol (PEG) 
and polymethcryloyloxyethyl phosphoryl choline (polyMPC)11 to improve efficacy. There 
are other formulations such as liposomes consisting of floxuridine and CPT-analog 
irinotecan,12 and micelles comprising of CPT derivative SN38.13 The nanostructured 
derivatives of CPT increase systemic exposure to CPT and anti-cancer activity in patients; 
however, the side effects are diarrhea, hepatic toxicity and renal failure.14,15 In addition, 
most nanoparticle-drug conjugates suffer from aggregation with hydrophilic and 
hydrophobic backbone of nanoparticles,16 and, therefore, low drug release.  
 In contrast, in the present work, we have developed a method to coat a 
bioresponsive polymer on elongated drug NRs. While conventional nanoparticles are made 
of lipids, metals and polymers, we prepared rod-shape nanoparticles using pure anti-cancer 
drugs, and deposited a thin layer (10.3 ± 1.4 nm) of bioresponsive polymer coating on drug 
NRs. Recent studies have shown that NRs enhance drug delivery as reflected in improved 
blood circulation time,17 specific receptor binding18 and cellular internalization by target 
cells.18 Theoretical models and in vivo biodistribution studies support these experimental 
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outcomes.17,19,20 Cationic cross-linked PEG hydrogel NRs are internalized by HeLa cells 
more rapidly than symmetrical shaped NPs.21 Mesoporous silica NRs of 450 nm length are 
taken up more rapidly than 250 nm rods or 100 nm spherical particles by A375 human 
melanoma cells.22 Rod-shaped particles can avoid phagocytosis depending on the initial 
contact angle to the macrophages.23 The adhesion strength of non-spherical particles 
towards the blood vessel wall is higher than spherical NPs, as shown in both experimental 
setting, and theoretical modeling.19,24-28 Accordingly, we prepared drug NRs in this work. 
We used the solvent diffusion method to prepare CPT NRs of 500.9 ± 91.3 x 122.7 ±10.1 
nm size in large quantities.29        
 We encapsulate CPT drug NRs with a bioresponsive polymer, PCL. This polymer 
is a FDA-approved biodegradable aliphatic polyester, and is well-known for hydrolytic 
cleavage of ester groups, and its non-toxicity.30  Nanoparticles composed of PCL polymer 
have been shown to exhibit increased blood circulation time, and reduced clearance by 
reticuloendothelial system (RES).31 PCL microspheres loaded with bovine serum albumin 
(BSA) protein released up to 60.5% of BSA in vitro.32 CPT, Doxorubicin and Taxol-loaded 
PCL microspheres efficiently released the loaded drugs from microspheres that resulted in 
a higher degree of cancer cell growth inhibition than free drugs.33-35 One drawback of these 
polymer-drug conjugates is drug’s aggregation with polymers,16 and, therefore, low drug 
release. To overcome these issues, we introduce a simple and rapid technique of interfacial 
polymer deposition on the surface of pure drug NRs in large quantities. The significance 
of our systems is that the NP shape provides greater contact surface area than conventional 
spherical NPs, and thus, ensures greater receptor ligand interactions for binding.36 We 
hypothesize that depositing a thin layer of PCL polymer on the surface of drug NRs would 
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not only protect drugs from degradation but also allow release of drugs at the target site 
due to specific receptor binding. We deposit a PCL coating from liquid precursors 
surrounding CPT NRs simultaneously during the drug NR formation.  
 Our nanocarrier system aims at selective breast cancer cell targeting by human 
epidermal growth factor 2 (HER-2) protein specific antibody conjugation. TTZ (Herceptin; 
Genentech) monoclonal antibody (mAb) binds to HER-2 overexpressed at the cell 
membrane by many cancer cells, including breast cancer cells.37 It is shown that TTZ-
conjugated polystyrene NRs accumulate in breast cancer cells by multivalent interactions 
with HER-2 receptors.26 TTZ reduces proliferation of breast cancer cells by binding to the 
extracellular domain of HER-2 receptors, preventing HER-2 dimerization, and thereby 
inducing subsequent cell cycle arrest in G1.38 In this study, we simultaneously delivered 
CPT and TTZ drugs using PCL coated NRs to achieve synergistic inhibition effects on 










2. MATERIALS AND METHODS 
2.1 SYNTHESIS OF PCL POLYMER COATED CPT NRs  
All reagents were purchased from Sigma-Aldrich unless otherwise specified. We 
deposited a thin layer of continuous PCL polymer (14,000 Da) film on CPT NRs using the 
solvent diffusion method.29 Briefly, 1 ml each of 10 mg/ml of CPT in DMSO and 1 mg/ml 
of PCL polymer in toluene were added to a 20 ml of reverse osmosis (RO) water using a 
syringe pump. Residual toluene was removed by stirring (300 rpm) the CPT-PCL NR 
suspension overnight at room temperature (R.T.; ~22oC). DMSO was removed by 
centrifugation at 3,000 rcf, followed by five times washing using RO water. PCL-coated 
CPT (CPT-PCL) NRs were freeze-dried, weighed and stored at 4oC. CPT concentrations 
were measured, and quantified by reading absorbance at 366 nm using a plate reader 
(BioTek Synergy), and the CPT calibration curve.18,29 The theoretical content of PCL 
weight in CPT-PCL NRs was calculated based on the weight of freeze-dried particles and 
CPT amount. Percent encapsulation efficiency of CPT and PCL were calculated based on 
their initial mass of samples. 
2.2 CHARACTERIZATION OF CPT-PCL NRs  
The morphology and size of CPT-PCL NRs were examined under transmission 
electron microscope (TEM; Tecnai F20) at an accelerating voltage of 120 kV. A drop of 
10 µl CPT-PCL solutions in water was air-dried on carbon-coated copper grids (Tedpella). 
The NR diameter, NR length, and thickness of the polymer coating were measured using 
ImageJ (version 1.45S, NIH, USA). Uncoated CPT NRs were imaged using a scanning 
electron microscope (SEM; Helios Nanolab 600 FIB). The surface charges of NRs in PBS 
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were determined by dynamic light scattering using a NanoSeries Zetasizer ZS 90 (Malvern) 
and the backscattering detection at 90o. The zeta potential was measured for 15 runs. Data 
was analyzed using means and standard deviations of three concentrations. 
2.3 DEGRADATION OF PCL COATING AND STABILITY OF LACTONE FORM   
      OF CPT IN CPT-PCL NRS  
The degradation of PCL coating, and conversion between lactone and carboxylates 
in CPT were analyzed by FT-IR spectroscopy. The disappearance of ester groups in PCL 
backbone, and appearance of carboxyl and hydroxyl groups were studied using FT-IR 
spectra. Briefly, CPT-PCL NRs were incubated for 72 h at 37oC in PBS at pH 6. Samples 
were freeze-dried to sublimate any water, and ground at 1:100 weight ratio with FT-IR 
grade potassium bromide (KBr; Alpha Aesar). Hydrolytic degradation was monitored by 
comparing the intensity of ester, alcohol and carboxyl bands at t=0 and 72 h for the same 
amount of PCL in NRs. To evaluate the conversion of active lactone rings into inactive 
carboxylic acids in coated NRs, CPT NRs alone without PCL coating was used as a control. 
The FT-IR absorbance spectra were obtained for 32 scans over the range of 4000 – 400 
cm-1 using a Thermo Nicolet Nexus 470 FT-IR. Background noises were subtracted from 
the spectra. All spectra were analyzed using EZ OMNIC E.S.P v.5.1 software. 
2.4 QUANTIFICATION OF CPT DRUG RELEASE  
CPT drug release was conducted by exposing CPT-PCL NRs to phosphate buffered 
saline (PBS) at pH 6 (to mimic the cancer microenvironment) and pH 7.4, and at 37oC. 
PBS of 500 µl were sampled at different time intervals of t = 0, 0.5, 2, 4, 8, 24, 36 and 72 
h. CPT drug concentrations, that were released to the buffer, were measured using 
absorbance at 366 nm and CPT standard curve. (These experiments were not run in 
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presence of fetal bovine serum (FBS) because FBS has high spectroscopic background 
noises). 
2.5 CONJUGATION OF ANTIBODY ON THE SURFACE OF CPT-PCL NRs 
TTZ antibody (Genentech) was conjugated to the surface of CPT-PCL NRs by 
coupling primary amines of TTZ with ester groups of PCL forming amide bonds. Briefly, 
10 mg/ml TTZ solution was prepared in PBS of pH 7.4. 10 mg CPT-PCL NRs were added 
to 1 ml of TTZ solution, mixed, and incubated at R.T. The unreacted reagents were 
separated using 100 kDa membrane filters (EMD Millipore Amicon Ultra-0.5). The 
supernatants were collected by centrifugation at 1,000 rcf, and analyzed by the BCA 
protein assay (Pierce Thermo Scientific). Bovine serum albumin (BSA) was used to 
prepare HER-2 non-targeted CPT-PCL-BSA NRs.  
2.6 IN VITRO CELL GROWTH INHIBITION 
The effectiveness of combination treatments using CPT-PCL-TTZ NRs was 
evaluated in HER-2 positive BT-474 breast cancer cells (ATCC) and HER-2 negative cell 
line MDA-MB-231 (ATCC). The cells were cultured in Hybri-Care (ATCC), and RPMI 
1640 (Life Technologies), respectively supplemented with 10% FBS (Corning) and 1% 
(100 units/ml) Penicillin-Streptomycin (Gibco) at 37oC and 5% CO2. Cells were plated in 
96-well tissue culture plates (Corning) at a density of 10,000 cells/well in 200 µl respective 
medium. After 18 h of growth, 10 µl of NRs were added to the medium. The final 
concentrations of CPT were 0.1, 0.2, 0.5, 1, 2, 5 and 10 µg/ml. The corresponding PCL 
concentrations were 2.9 5.8, 14.6, 29.1, 58.2, 145.5 and 291.1 µg/ml, respectively, and 
TTZ concentrations were 0.4, 0.8, 1.9, 3.8, 7.5, 18.8 and 37.7 µg/ml, respectively. CPT-
PCL-BSA was used as HER-2 non-specific control. Cells were also treated with the same 
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concentrations of PCL solutions to determine its cytotoxic effects. Cells treated with 10 µl 
of PBS were used as positive controls. 3 h later, the medium was replaced with fresh 
medium. After 72 h, the plates were centrifuged at 100 rcf for 15 min. The supernatant was 
discarded. Live cells were stained with 2 µM calcein AM (Life technologies) in PBS by 
incubating at R.T. for 30 min. The fluorescence intensity (F.I.) of calcein AM was 
measured using 485/528 excitation/emission filters using the plate reader (BioTek Synergy 
2). The percentage inhibition in cell growth was calculated using the following equation 
(1): 
% 𝑖𝑛𝑖ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑖𝑛 𝑐𝑒𝑙𝑙 𝑔𝑟𝑜𝑤𝑡ℎ =
𝐹.𝐼.𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠−𝐹.𝐼.𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝐹.𝐼.𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
× 100 (1) 
To examine that the cell growth inhibitory effects were induced by NRs 
intracellularly, BT-474 cells were incubated with CPT-PCL-TTZ NRs for 6 h at 37C in 
8-well glass chambers (Lab-Tek). TTZ was labeled with Alex Fluor 594 dye according to 
the manufacturer (Molecular Probes)’s protocol. After 2 h of NR incubation, the cells were 
washed with PBS three times to remove unbound particles, and re-incubated with medium 
for 4 h. Cells were imaged using a scanning laser inverted confocal microscope (Ti-Eclipse; 
Nikon) and 40x objective. The excitation/emission used for CPT and Alexa Fluor 594 were 
360/400 and 590/617 nm, respectively. 
2.7 STATISTICAL ANALYSIS 
Each experiment was carried out with three independent experiments of at least 




3.1 PREPARATION OF A THIN LAYER OF PCL COATING ON CPT NRs 
We developed an engineering technique based on the solvent diffusion method to 
prepare PCL coated CPT NRs of 500.9 ± 91.3 nm x 122.7 ± 10.1 nm in length and width, 
respectively (Fig. 3.1 (a)). This process involved 3-steps: phase separation, CPT NR 
 
 
Figure 3.1: TEM images of CPT-PCL NRs. (a) Image showing homogeneous distribution of CPT-
PCL NRs. (b) Magnified view of a thin (~10 nm; arrows) PCL polymer film on CPT NRs. (c) 






formation and PCL deposition. CPT NRs were formed because of phase separation from 
the DMSO oil phase into water under mild stirring (~300 rpm).18,29 At the same time, 
continuous PCL polymer films were coated on CPT NRs by virtue of van der Waals 
attractive forces between CPT NR surface and PCL polymer under low shear stress.39 The 
combination of adhesive and shear forces spread the polymer thinly over CPT NRs. A thin 
layer of 10.3±1.4 nm PCL coating was formed surrounding the CPT NR (Fig. 3.1(b) and 
Fig 3.1(c)). This is a soft coating technique that does not require high mechanical agitation, 
sonication or vibration, thus preventing any structural damage of drugs. The encapsulation 
efficiency of drug: copolymers were reported 0.02 to 0.15.40 Zeta potentials of CPT NRs 
and CPT-PCL NRs were measured as -26.8 ± 7.71 mV (Fig. 3.2(a)) and -15.5 ± 3 mV (Fig. 
3.2(b)) in PBS, respectively. An increase in zeta potential for CPT-PCL NRs indicates the 
deposition of the polymer on the surface of CPT NRs. 
3.2 DEGRADATION OF PCL COATING USING FT-IR SPECTROSCOPY 
The degradation of functional groups of PCL coating was determined by FT-IR 
analysis (Fig. 3.3). The infrared spectra of CPT-PCL NRs were compared before (t=0; Fig. 
3.3, top, dotted line) and after (t=72 h; Fig. 3.3, middle, solid line) incubation in PBS at pH 
6 that mimics the slightly acidic cancer microenvironment. The presence of strong band at 
1746 cm-1 is due to the presence of ester carbonyl group that corresponds to the –CO 
stretching in PCL polymer coating before degradation (dotted line). The band intensity at 
1746 cm-1 decreased after 72 h due to hydrolytic cleavage of ester bonds at pH 6 (solid 
line). The peak at 1288 cm-1 represents C-C and C=O stretching in the PCL polymer 
backbone,41 which decreases in intensity at t=72 h. The peaks at 2860 and 2930 cm-1 
correspond to the characteristic absorption of the C-H stretching bonds of ԑ-CL. The 
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appearance of two peaks at 1460 and 2370 cm-1 in t=72 h spectra are characteristics of -




Figure 3.2: Surface zeta potential of CPT NRs (a) before PCL coating, and (b) after PCL coating as 





OH functional group in carboxylic acid (-COOH) indicating the hydrolysis of ester bonds. 
The peak at 3420 cm-1 indicates the presence of H-O-H stretching in water that increases 
in intensity slightly at t=72 h. The absorption band of hydroxyl group is also present at t=0 
h with a slightly shorter peak, which, may be, due to absorption of moisture from the 
 
Figure 3.3: FT-IR graphs of CPT-PCL NRs at t=0 (dotted line), t=72 h (solid line) and CPT NRs 
without any coating 
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atmosphere. The FT-IR spectra of CPT NRs without PCL coating (Fig. 3.3, bottom, dash 
line) shows carbonyl stretching for cyclic ester (lactone) at 1630 cm-1 and C-C(=O)-O 
stretching for carboxylate at 1294 cm-1.42 We calculated the ratio of intensity peaks of 
lactone: carboxylate that was 2.81 in uncoated CPT NRs. This ratio of lactone: carboxylate 
decreased to only 0.8 in CPT-PCL NRs suggesting the protection of an active form of 
lactone rings underlying the PCL coating. 
3.3 CPT DRUG RELEASE WITH PCL COATING DEGRADATION 
The percentage of CPT release at different time intervals is shown in Fig. 3.4 as 
calculated using the CPT standard curve (Fig. 3.5). A slow release was observed at pH 6 
 
Figure 3.4: Cumulative percentage of CPT drug release from CPT-PCL NRs in PBS buffer at 





(solid line) with 8.2% CPT release in the first 0.5 h following 32.6% release after 8 h, and 
51.5% after 72 h. The release rate is comparable with the release patterns of CPT from 
poly(D,L-lactide-co-glycolic acid) (PLGA) microspheres,43 and HCPT-1 from PCLLA-
PEG-PCLLA.33 At pH 7.4 (dotted line), the release profile was slower, and it needs almost 
72 h to reach ~30% release, indicating the coating effect of bioresponsive PCL barrier. 
CPT was released from PCL-coated NRs at pH 6 by hydrolytic disruption of PCL coating 
and the drug’s diffusion. 
3.4 PREPARATION OF ANTIBODY TARGETED CPT-PCL-TTZ NRs  
 TTZ antibody was conjugated on the surface of CPT-PCL NRs by amide bond 
formation between the ester groups of polymer and amines on the antibody. The advantage 
 




of this method is the avoidance of preliminary modifications of the antibody such as 
activation by carbodiimide that reduces its activity.46 TTZ covalent binding will help to 
deliver the NRs at breast cancer cells. The encapsulation efficiency was expressed as  
the weight ratio among CPT, PCL and proteins (TTZ or BSA) incorporated in NRs (Table 
3.1). The protein concentrations were measured using the BCA protein assay and BSA 
standard curve (Fig. 3.6). The weight ratio of CPT: PCL: TTZ and CPT: PCL: BSA were 
calculated as 12: 1: 9 and 13.9: 1: 9.4, respectively (Table 3.1). Table 3.2 shows the 
percentage encapsulation of CPT, PCL, TTZ and BSA in respective NRs. 
 





Table 3.1: Characterization of CPT-PCL-TTZ and CPT-PCL-BSA NR 
conjugates 
 
CPT in CPT-PCL-TTZ NRs, mg 4.8 ± 1.3 
PCL in CPT-PCL-TTZ NRs, mg 0.4 ± 0.05 
TTZ in CPT-PCL-TTZ NRs, mg 3.7 ± 1.6 
CPT: PCL: TTZ  (w: w ratio) 12 : 1 : 9 
CPT in CPT-PCL-BSA NRs, mg 5 ± 0.8 
PCL in CPT-PCL-BSA NRs, mg 0.36 ± 0.9 
BSA in CPT-PCL-BSA NRs. mg 3.4 ± 1.7 
CPT: PCL: BSA (w: w ratio) 13.9 : 1 : 9.4 
 
Table 3.2: Encapsulation efficiency for CPT, PCL, TTZ and  BSA in NR forms 
 
Component % encapsulation/ conjugation efficiency 
CPT 49.2 ± 1.1 
PCL 39.9 ± 5.9 
TTZ 41.1 ± 1.8 
BSA 33.7 ± 1.8 
 
3.5 INHIBITION OF BREAST CANCER CELL GROWTH BY CPT-PCL-TTZ NRs 
The therapeutic activity of CPT-PCL-TTZ NRs was evaluated in HER-2 positive 
BT-474 (Fig. 3.7) and HER-2 negative MDA-MB-231 cells (Fig. 3.8) at varying 
concentrations. These are the previously reported doses of CPT in human breast cancer 
cells.7,8,29,47 The NRs inhibited the growth of HER-2 positive BT-474 cells in a dose 
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dependent manner. The combination of CPT and TTZ using CPT-PCL-TTZ NRs inhibited 
up to 61.6% BT-474 cell growth at 10 µg/ml. At this concentration, CPT-PCL-TTZ NRs 
inhibited the cell growth 1.5 fold more than CPT-PCL-BSA NRs. The difference in growth 
inhibition between CPT-PCL-TTZ and CPT-PCL-BSA indicates the antibody dependent 
growth inhibition effects of TTZ on HER-2 positive BT-474 cells.48,49 Surprisingly HER-
2 negative MDA-MB-231 cell line was also sensitive to the NRs (Fig. 3.8). No difference 
between CPT-PCL-BSA and CPT-PCL-TTZ was found in these cells, indicating non-





















Figure 3.7: Growth inhibition curves of HER-2 positive BT-474 cells as determined by calcein-
AM live dead assay after 72 h incubation. Results are expressed as a percentage of PBS-treated 
control cells versus doses of CPT in CPT-PCL-TTZ NRs. The data represent average and 











Figure 3.8: Growth inhibitory effects of CPT-PCL-TTZ NRs on HER-2 negative MDA-MB-
231 cells. No difference between CPT-PCL-TTZ and CPT-PCL-BSA control indicates non-







Our proposed polymer-coated drug NRs have advantages over uncoated drugs in 
that they can avoid rapid body clearance, have fewer side effects in normal healthy cells, 
and can protect drugs from premature degradation. At physiological pH, the unstable E-
ring lactone in CPT is converted to carboxylate form, which possesses high affinity to 
human serum albumin (HSA) and is preferentially eliminated.1,2 This is a clinical hurdle to 
CPT therapeutic efficiency. Encapsulation of CPT inside PCL polymer coating prevents 
CPT from being converted into the inactive carboxylate form during blood circulation, thus 
increasing its likelihood of reaching the tumor intact.50,51 As it is observed from the FT-IR 
data (Fig. 3.3) that the PCL coating undergoes hydrolytic degradation producing non-toxic 
by-products (alcohol and water). Slow degradation of the polymers released CPT drugs 
from NRs at pH 6 (Fig. 3.4; solid line). At pH 7.4, PCL polymer coating does not allow for 
fast CPT penetration (Fig. 3.4; dotted line).       
 The elongated NR design allows for long circulation time in the body,24,26,52-54 and 
multivalent interactions with tumor cells,21,55,56 increasing the probability of receptor-
ligand interactions. It is shown that the active targeting of breast cancer cells using the 
similar dimension of NRs of CPT with TTZ attached to the breast cancer cell surface.18,29 
Due to the fluid dynamics induced by the unique rod shape, these nanoparticles flow along 
the edges of blood vessels. By flowing along the sides of blood vessels, nanoparticles fall 
to the tumor due to gaps in the endothelial cell wall between the tumorous tissue and blood 
vessels.57 The layer of TTZ antibody on the surface of NRs offers additional feature of 
targeted therapy.                                                                                                                       
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The tumor microenvironment is slightly more acidic (pH ~6) than the blood (pH 
7.4).58,59 We simulated the condition using PBS at pH 6 and determined the effects on the 
stability of NRs. The release of CPT in the first 30 minutes was minimal, with only 7.4% 
of the total CPT drugs in NRs being released (Fig. 3.4; solid line).  The polymer coating 
begins to disintegrate, releasing ~40% of total CPT in 24 h and more than 50.8% in 72 h.
 Interaction with cancer cells is important for most nanoparticles reaching the target 
site. By changing nanoparticle geometry from spherical to rod-shape, receptor-ligand 
interactions can be enhanced up to 2.5 fold by multivalency effects.18 We accomplished 
active targeting by conjugating TTZ to the surface of CPT-PCL NRs. By using both CPT 
and TTZ, which use different mechanisms of actions of cytotoxicity, we find increased 
therapeutic efficacy over those of traditional monotherapies. CPT is a topoisomerase I 
(topoI) inhibitor that selectively affects cancer cells by exerting S-phase cytotoxicity and 
G2-M cell cycle arrest.1,2 TTZ induces cell cycle arrest in the G1 phase leading to 
apoptosis.37,38 While CPT is cytotoxic and the single agent therapeutic response rate of 
TTZ is low (~26%),6,33,37,48,49,60-62 the combination approach is more effective in treating 
cancers than monotherapies, as the probability of acquiring resistance to two simultaneous 
treatments is the square of the probability of resistance to a single agent.  
 We observed that HER-2 negative MDA-MB-231 cell line was sensitive to NRs 
(Fig. 3.8). No difference between CPT-PCL-BSA and CPT-PCL-TTZ was found in these 
cells. We conjecture that this might be due to effective non-specific endocytosis in in vitro 
setting. We anticipate difference in targeting efficiency shall be observed in in vivo setting. 
Collectively, our results support a purely cytostatic effect of these drugs in vitro, we are 
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currently at the stage of performing in vivo experiments to examine this combination in 




















We have developed a simple method of thin (10.3±1.4 nm) layer of bioresponsive 
PCL polymer coating on CPT anti-cancer drug NRs. As the drug molecules precipitated 
out of its organic solvent into an aqueous phase, the molecules aggregated and formed NRs. 
The PCL polymers spread thinly over drug NRs due to van der Waals and hydrogen 
bonding effects. This process did not produce any adverse mechanical effects to prepare 
the NRs, thereby, retaining active structures of therapeutic drugs. One merit of our method 
is the preparation of PCL-coated CPT NRs of (500.9±91.3 x 122.7±10.1) nm size in large 
quantities. We characterized the degradation of CPT-PCL NRs using FT-IR analysis, and 
release of CPT in a simulated pH condition in caner microenvironment. Conjugation of 
TTZ to the surface of CPT-PCL NRs significantly inhibited the growth of BT-474 breast 
cancer cells. Overexpression of HER-2 increases breast cancer cell proliferation in part by 
transactivation of enhanced growth factor receptor (EGFR) signaling.37,48,61 Blocking of 
HER-2 by selective TTZ binding proved to suppress the cells growth. In vivo studies are 
needed for therapeutic efficacy.  Nonetheless, our current results found thus far are 
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II. POLYMER COATING ON Au-Fe3O4 NANOPARTICLES 
ABSTRACT 
 Nanoparticle synthesizing methods have been widely studied for cancer treatment. 
However, aggregation of nanoparticles inside the blood vessel remains a problem for 
cancer treatment. The aggregation of the nanoparticles inside the vessel reduces the 
potential and ability of the nanoparticles by blocking access to the targeted site and 
removing them from the body. Here, we report a simple and fast method to solve the 
problem by depositing a thin layer of biocompatible polymers on the surface of 
nanoparticles to reduce the chance of collision of the nanoparticles, which will prevent 
them from aggregation. The thin layer (1.81 ± 0.60 nm) of poly-l-lysine (PLL) and 
polyethylene glycol (PEG) was deposited on Au-Fe3O4 nanoparticles. The average size of 
the nanoparticles was 58.27 ± 7.48 nm. The nanoparticles were uptaken by the breast 
cancer cells. The Au-Fe3O4 nanoparticles showed the toxicity to the breast cancer cells at 
500 µg/ml. The NIR laser with Au-Fe3O4 nanoparticles was able to induce the 
hyperthermia effect to cells.  These results suggest the optimal concentration of Au-Fe3O4 
nanoparticles and the coating method to use in breast cancer treatment using the 








Current cancer treatment methods have been focusing on noninvasive techniques. 
One of the interesting approaches is the hyperthermia effect. The hyperthermia effect 
occurs when the temperature is in the range of 39-42 oC for at least 1 hour.18 At this 
temperature range, the effects (including inhibition of radiation that induces the damage 
repair, changes in perfusion, and re-oxygenation) are able to improve the therapy in the 
tumor sites.19 One approach to the method of inducing hyperthermia effect is delivering 
metal nanoparticles to the tumor site. Gold nanoparticles have been studied due to their 
biocompatibility to the human body and cost-effective approach for cancer treatment.20 
Surface plasmon resonance (SPR) is the phenomenon that the electromagnetic field at a 
certain wavelength stimulates the free electrons across the surface of gold nanoparticles. 
As a result of SPR, the particles released the heat after they absorbed the electromagnetic 
field.21 Various types of gold nanoparticles have been synthesized and used for 
hyperthermia-inducing therapy, such as gold nanoshells,22 gold nanorods,23 and gold 
nanospheres.24 Near Infrared (NIR) wavelength (800-1300 nm) plays an important role in 
order to induce the SPR of gold nanoparticles because gold nanoparticles highly absorb the 
wavelength in this region.25        
 Even though gold nanoparticles were found useful for cancer treatment, there is 
still a drawback to this method. The disadvantage is the low retention time, as nanoparticles 
started to accumulate in the tumor site at high concentration.26 In order to solve this 
problem, we coated the surface of the gold nanoparticle with biocompatible polymer PLL 
and PEG to prevent them from aggregation. PLL is the biocompatible cationic polymer 
that provides active amino groups that are useful for drug delivery and cell adhesion.27 
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Coating PLL on the surface of metal nanoparticles resulted in increased retention time of 
silver nanoparticles.28 PEG is a neutral polyether, which is water soluble and has an ability 
to form two phases with other polymers. In addition, this polymer is non-toxic to cells.29         
            In this study, we coated Au-Fe3O4 nanoparticles with PLL together with PEG to 
create a polymer layer around the gold nanoparticles. We hypothesize that coating polymer 
on the surface of these nanoparticles will result in increased the retention time and 
















2. MATERIALS AND METHODS 
2.1 PLL COATING ON Au-Fe3O4 NANOPARTICLES 
 All reagents were purchased from Sigma-Aldrich unless otherwise specified. 
Briefly, 25 mg/ml of bare gold nanoparticles was prepared in 1 ml of water. Then, 653 µL 
of 0.1% w/v of PLL was added to nanoparticles. After 1 minute of mixing, 250 µl of 1% 
w/v PEG was added to the mixture per 10 ml of mixture. The whole suspension was stirred 
for 5 minutes. The excess PLL and PEG were removed by centrifuging at 5,000 rcf for 30 
minutes. The amount of PLL was quantified using Trypan Blue assay, which was modified 
from Grotzky et al.30  
2.2 PLL- Au-Fe3O4 NANOPARTICLE CHARACTERIZATION 
 The morphology and size of nanoparticles were characterized by using a 
transmission electron microscope (TEM, Tecnai F20) at an accelerating voltage of 120 kV. 
A drop of 10 µl of sample was air-dried in carbon coated copper nanogrid (Tedpella). The 
size of Au-Fe3O4 and polymer coating thickness were measured using ImageJ (version 
1.45S, NIH, USA).       
2.3 BT-474 CELL CYTOTOXICITY WITH Au-Fe3O4 NANOPARTICLES 
 To estimate the optimal concentration of Au-Fe3O4 nanoparticles, BT-474 cells 
were cultured in Hybri-Care (ATCC) media supplemented with 10% Fetal Bobine Serum 
(FBS) and 1% (100 units/ml) Pennicillin-Streptpmycin (Corning) at 37 oC and 5% CO2 
respectively. Then, cells were plated in a 96- tissue culture well plate at a density of 10,000 
cells per well in 200 µl of media. After 18 hours of growth, Au-Fe3O4 nanoparticles were 
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added to the medium. The final concentrations of Au-Fe3O4 nanoparticles were 500, 100, 
50, 10, 5 and 1 µg/ml. The media was replaced to remove non-uptaken nanoparticles after 
3 hours of incubation. After 72 hours, the plate was centrifuged down at 100 rcf for 15 
minutes. The supernatant was discarded. Live cells were stained with 2 µM of Calcein AM 
(Life technologies) in PBS. The percentage of dead cells was calculated using equation 1. 
% 𝑖𝑛𝑖ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑖𝑛 𝑐𝑒𝑙𝑙 𝑔𝑟𝑜𝑤𝑡ℎ =
𝐹.𝐼.𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠−𝐹.𝐼.𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝐹.𝐼.𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
× 100.                              (1)      
 In order to examine the cell apoptosis effects induced by PLL-coated gold 
nanoparticles, BT-474 cells were incubated with PLL-coated gold nanoparticles for 3 hours 
at 37 oC in a 96-tissue culture well plate. After the incubation, the cells were washed with 
sterilized PBS three times to remove non-uptaken nanoparticles.  
2.4 IN VITRO CELL APOPTOSIS STUDY 
 The apoptosis study of PLL-coated gold nanoparticles was evaluated using HER2+ 
breast cancer cell line (ATCC). The cells were plated in a 96-tissue culture well plate at a 
density of 10,000 cells per well in 200 µl of media. After 18 hours of growth, 10 µl of PLL-
coated gold nanoparticles was added to the medium. The final concentrations of PLL-
coated nanoparticles were 100, 50, 10, 5 and 1 µg/ml. The media was replaced with fresh 
media to remove the non-uptaken nanoparticles after 3 hours of incubation. Then, the cells 
were treated with a NIR wavelength laser (790 nm) at 1 W/cm2 for 1 minute. After 72 
hours, the plate was centrifuged down at 100 rcf for 15 minutes. The supernatant was 
discarded. Live cells were stained with 2 µM of Calcein AM (Life technologies) in PBS. 
The plate was then incubated at R.T. for 45 minutes. The fluorescent intensity (F.I.) was 
measured using 485/528 filters using a plate reader (BioTek Synergy 2).     
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RESULTS     
3.1 CHARACTERIZATION OF PLL-Au-Fe3O4 NANOPARTICLES 
 Because the shape of Au-Fe3O4 nanoparticles is both hexagonal and square, the 
equivalent diameter was used to measure the size of nanoparticles. The equivalent diameter 
of Au-Fe3O4 nanoparticles is 58.27 ± 7.48 nm, as shown in Fig 3.1 (a), while the PLL-Au-
Fe3O4 nanoparticles diameter is 60.56 ± 7.18 nm. The thickness of the PLL coating is 1.81 
± 0.60 nm as shown in Fig 3.1 (b).   
3.2 CELLULAR UPTAKE OF Au-Fe3O4 NANOPARTICLES 
 Despite the size of Au-Fe3O4 nanoparticles, the intracellular uptake of Au-Fe3O4 
nanoparticles were examined. The microscopic images confirmed the delivery of 
 






nanoparticles inside the cells (Fig.3.2), indicating that the nanoparticles were uptaken 
inside the cells. No nanoparticles were found outside the cells. 
3.3 BT-474 CELL CYTOTOXICITY WITH Au-Fe3O4 NANOPARTICLES 
 According to Fig. 3.3, the Au-Fe3O4 nanoparticle at low concentration (up to 100 
µg/ml) was found to have negligible cytotoxic effect to the cells, whereas the percentage 
of cell death increased to ~40% at 500 µg/ml, which might be the effect of the aggregation 
of nanoparticles.  
3.4 EFFECTS OF THE Au-Fe3O4 NANOPARTICLE WITH NIR LASER TO  
       BT-474 CELLS 
After the optimal concentration of Au-Fe3O4 nanoparticles that did not cause 
cytotoxicity to BT-474 cells was known, the cells were incubated within that concentration. 
The cells were then exposed to NIR laser for 1 min. The results indicated that after the Au-
Fe3O4 nanoparticles, uptaken cells were exposed to the laser, the percentage of death cells 
increased in every concentration, as shown in Fig. 3.4. The laser-PBS treated cells were 
 
Figure 3.2 :  Microscopic images of (a) Cellular uptake of 100 µg/ml of Au-Fe3O4 nanoparticles 






used as a control. The laser itself did not show toxicity to cells but the cells with the same 
concentration without using laser showed a negligible effect of toxicity to cells. For 























cell death while non-laser treated cells showed only ~24% of cell death. The same trend 
also occurred at other concentrations of Au-Fe3O4 nanoparticles. This can be the evidence 
to confirm that the NIR laser can be used to induce the hyperthermia effect, which caused 
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 The simple method to coat the surface of Au-Fe3O4 nanoparticles using both 
biopolymers, which are PLL and PEG was proposed. The particles themselves aggregated 
within the cells after they were uptaken by the cells. The microscopic images confirmed 
the cellular uptake of the nanoparticles. Most of the nanoparticles were found inside the 
cells. We also found that at the final concentration of 500 µg/ml, Au-Fe3O4 nanoparticles 
showed some cytotoxicity to BT-474 cells. This was due to nanoparticle aggregation. The 
NIR laser at 0.9-1.1 W/cm2 for 10-15 minutes has been proved to maximize control of 
tumor growth in mice and minimize damage to surrounding cells.31 It was also found that 
after exposing the cancer cell with NIR laser when incubated with Au nanorods, the 
efficacy of nanorods was intensified due to the increased efficiency of NIR absorption and 
photothermal conversion.32 The hyperthermia effects, which increased the temperature to 
41.5 oC, could be induced by exposing the NIR laser on the gold nanoparticles in the mice, 
which finally decreased the tumor volume.33 Moreover, the apoptosis of cancer cells was 
also found to be evident after a combination of using the NIR laser at 1 W/cm2 and gold 
nanoparticles.34 The results indicated that after using the NIR laser on the cells with Au-
Fe3O4 nanoparticles, they can increase the cell death due to the hyperthermia effects. 
However, these nanoparticles need specific targeting ability to reach the tumor site because 
some nanoparticles were found in other organs from in vivo studies.33  
 





 We have developed a fast and simple technique to coat the surface using 
biopolymers. The thin layer (1.81 ± 0.60 nm) of biopolymer was deposited on the surface 
of Au-Fe3O4 nanoparticles. The nanoparticles were uptaken inside the cells. At high 
concentration of Au-Fe3O4 nanoparticles at 500 µg/ml, the percentage of dead cells 
increased, which indicated the cytotoxic effect of these nanoparticles. In contrast, there was 
negligible cytotoxic effect to the cells at lower concentrations. The uncoated Au-Fe3O4 
nanoparticles were able to use for cancer treatment by inducing hyperthermia effects to 
cells after exposing the cell with Au-Fe3O4 nanoparticles with NIR laser. These results 
recommend the optimal concentrations of using the Au-Fe3O4 nanoparticles to use in the 
study of induced hyperthermia effects for cancer therapy and show that our Au-Fe3O4 
nanoparticles can be used to treat the cancer by inducing hyperthermia effects to cancer 
cells. However, future studies are needed, including studies on the stability study of the 
nanoparticles, the amount of each polymer quantification, and in vitro studies of 









2. CONCLUSIONS AND FUTURE WORKS 
In this study, polymer-coated anticancer drug-encapsulated NRs were prepared by 
the solvent diffusion method. The mean size of PCL-coated CPT NRs was 500.9 ± 91.3 
nm in length and 122.7 ± 10.1 nm in width. The anticancer drug-encapsulated NRs have 
the ability to degrade in the acidic environment present in tumor sites. Then, the released 
drug diffuses into the pores of the polymer and then into cancer cells. In this study, the 
conjugation of TTZ on NRs enabled the NRs to specifically target only the breast cancer 
cells. It was found that the specific targeting anticancer drug-encapsulated NRs 
significantly inhibited the BT-474 breast cancer cell growth. Although in vitro studies 
showed high possibility to inhibit breast cancer cell growth, this study still needs evidence 
from in vivo studies for therapeutic efficacy.      
 In addition, biopolymer coating on the surface of Au-Fe3O4 nanoparticles is one 
technique to solve the aggregation problem of these nanoparticles. Coating biopolymer on 
nanoparticles provide advantages for biomedical applications, especially for drug delivery. 
Therefore, the study of coating polymer on nanoparticles rather than using the drug as drug-
encapsulated nanoparticles might be able to increase the potential of nanoparticles such as 
gold nanoparticles, which are used in early detection of cancers and cancer therapy. The 
study showed the feasibility study of using Au-Fe3O4 nanoparticles with the principal of 
thermal therapy; however, the further studies are needed for more evidence, such as the 
quantification of PLL and PEG on the surface of nanoparticles, in vitro studies of using 
NIR laser to induce cell apoptosis by the hyperthermia effect, and in vivo studies for 
treatment efficacy.    
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